RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
168 hedge funds and large institutions have $1.14B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2022 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 55 increasing their positions, 44 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
6% more funds holding
Funds holding: 159 → 168 (+9)
30% less call options, than puts
Call options by funds: $22.6M | Put options by funds: $32.3M
Holders
168
Holding in Top 10
3
Calls
$22.6M
Puts
$32.3M
Top Buyers
| 1 | +$40.5M | |
| 2 | +$38.3M | |
| 3 | +$34.1M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$18M |
| 5 |
Morgan Stanley
New York
|
+$16M |
Top Sellers
| 1 | -$45.5M | |
| 2 | -$12.6M | |
| 3 | -$11.1M | |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$8.55M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$7.41M |